Neurosearch expected to licence its promising cancer drug Endovion  

Following good early results Neurosearch expects to licence Endovion to an international pharmaceutical company

Danish biotech company Neurosearch has presented positive preclinical and Phase clinical 1 trials of their cancer drug Endovion. The compound inhibits the formation of new blood vessels (angiogenesis) by affecting a chloride channel which is important for cell division and cell migration. From the perspective of cancer treatment it means that the neoplasm is hindered in getting a supply of growth nutrients.


The new trials have shown that mice with an aggressive type of brain tumour survive significantly longer if they are treated with a combination of Endovion and Temozolomide (a cytochrome P450-independent prodrug – Ed) than if they only were treated with Temozolomide. According to leading Danish oncologists there is a great clinical need for a new drug with Endovion’s profile. Neurosearch is expecting to enter a development and licence agreement with an international pharmaceutical company on Endovion. The news is reported by Biotechdenmark and on Neurosearch’s website.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×